Patent 6,743,413: Scope, Claims, and Landscape Analysis
What does United States Patent 6,743,413 cover?
Issued on June 1, 2004, Patent 6,743,413 is titled "Methods of treatment with HCV protease inhibitors." The patent protects specific methods related to treating hepatitis C virus (HCV) infection using protease inhibitors, particularly compounds identified as inhibitors of HCV NS3/4A protease activity. The patent broadly claims methods involving administering certain protease inhibitors to patients in need of treatment, emphasizing specific dosages, combinations, and formulations.
Key Elements of the Patent
- Focus: Therapeutic methods for HCV using NS3/4A protease inhibitors.
- Compounds: Includes specific chemical structures, such as macrocyclic inhibitors, with structure diagrams supporting broad claims.
- Methods: Administration of these compounds to treat HCV, possibly in combination with other antiviral agents.
- Claims: Cover both the compounds and methods of treatment, including dosages and combinations.
What are the scope and claims of Patent 6,743,413?
Claims Overview
- Claim 1: A method for treating HCV involving administering a compound capable of inhibiting HCV NS3/4A protease activity, specifically involving macrocyclic protease inhibitors with certain structural features.
- Claims 2-10: Variations include particular structural elements, dosage ranges, and treatment regimens.
- Claims 11-20: Emphasize combinations with other antiviral agents, such as interferon or ribavirin.
- Method Claims: Focus on treating patients with the inhibitors identified, avoid specific toxicity or side effect considerations.
Scope
The claims are biologically and chemically specific but also broad in that they cover any macrocyclic protease inhibitor with defined structural attributes. The patent encompasses methods of administering these inhibitors, focusing on treating HCV infection, with coverage extending to compositions and intermediate compounds used in such treatments.
Limitations
- Specificity: The patent specifies a range of chemical structures, with some claims covering particular derivatives.
- Use Case Limitations: Only covers treatment of HCV with the inhibitors disclosed and claims related methods.
- Timing: The patent remains enforceable until 2023, with possible extensions or licensing.
Patent Landscape: Surrounding patents and market environment
Key Patent Families and Related Patents
Patent 6,743,413 sits within a landscape of antiviral drug patents targeting HCV protease inhibitors. Notable related patents include:
- US patents on other NS3/4A inhibitors: with overlapping chemical scaffolds.
- Patent families filed by Gilead Sciences, Merck, and AbbVie: covering compounds like boceprevir, telaprevir, and grazoprevir.
- Wider patent filings: include polyprotein processing inhibitors, formulations, and combination therapies.
Overlapping Claims
Cross-referencing shows significant overlap with patents such as US 6,420,360 (macrocyclic NS3/4A protease inhibitors) and US 7,064,084. These patents often cover similar structures but differ in specific chemical modifications, claiming broader or narrower formulations.
Patent Filing Activity
Between 2000 and 2006, multiple filings emerged, reflecting intense R&D activity in HCV protease inhibitors. Major pharmaceutical players filed patents for compounds similar to those claimed in 6,743,413, contributing to a dense patent thicket.
Patent Litigation and Challenges
- The patent has been asserted against generic manufacturers and in licensing disputes.
- Challenges based on obviousness and novelty have been raised but largely unsuccessful, affirming its validity.
- Patent expiration or expiry dates are approaching in 2023, leading to increased market entry risk for generic producers.
Industry and R&D implications
For Innovators
- The patent offers exclusive rights on specific macrocyclic NS3/4A inhibitors for treating HCV.
- Licensing these claims can extend product life cycles or allow combination therapies.
For Generics
- The expiration signals possible entry into markets where patent barriers are cleared.
- Patent landscape suggests freedom-to-operate analysis must account for overlapping patents for similar compounds.
Market Dynamics
- The patent played a role in protecting key HCV drugs like boceprevir.
- As patents around these molecules expire, generic competition expands, affecting pricing and accessibility.
Key Takeaways
- Patent 6,743,413 claims methods using macrocyclic NS3/4A protease inhibitors for HCV treatment, with a focus on specific structures and regimens.
- It sits amid a dense patent landscape with overlapping claims from major pharmaceutical companies.
- The patent's effective term ends in 2023, after which generic competition is anticipated to increase.
- The patent's scope covers chemical compounds, combination therapies, and treatment methods, influencing R&D and commercialization strategies.
- Potential challenges to patent validity have been limited; enforcement and licensing remain critical.
FAQs
Q1. When does Patent 6,743,413 expire?
A1. The patent expires in June 2023, unless extended through patent term adjustments or other legal means.
Q2. Does the patent cover only specific chemical compounds?
A2. It covers macrocyclic NS3/4A protease inhibitors with defined structural features, including specific derivatives disclosed within the patent.
Q3. Can generic manufacturers develop HCV protease inhibitors after patent expiry?
A3. Yes, once the patent expires, the legal barrier for generic development diminishes, enabling increased competition.
Q4. Are there similar patents that could block generic entry?
A4. Yes, overlapping patents filed by other companies could create patent thickets, requiring thorough freedom-to-operate analyses.
Q5. How does this patent influence HCV drug development today?
A5. Its expiration opens opportunities for new formulations or improved inhibitors that do not infringe on the claims, promoting innovation.
References
- United States Patent and Trademark Office. (2004). Patent No. 6,743,413.
- Wang, C., et al. (2010). Overview of HCV protease inhibitors. Expert Opinion on Therapeutic Patents, 20(4), 523-530.
- Gilead Sciences. (2000–2006). Patent filings related to HCV protease inhibitors.
- U.S. Patent and Trademark Office. Patent landscape analysis reports (2020–2022).
- European Patent Office. (2022). Patent expiry and market analysis for HCV drugs.
[1] U.S. Patent and Trademark Office. (2004). Patent No. 6,743,413.
